Refine by
Therapeutics Unveils Model Development Articles & Analysis: This-Year
6 news found
Ace Therapeutics, a biotechnology company pioneering novel central nervous system (CNS) delivery solutions, today announced the release of its BBBporter™ technology platform. This innovative platform is specifically designed to overcome the primary challenge in treating brain diseases: the blood-brain barrier (BBB). By leveraging a suite of biomimetic and AI-powered technologies, ...
With years of experience in the pharmaceutical and life science sectors, CD Bioparticles has announced the launch of its custom Enzyme-Conjugated Particles synthesis services. These particles are primarily polymer- and inorganic-based, and biomolecules and enzymes can be conjugated to them in different ratios for various applications. Due to their unique specificity and high activity, enzymes ...
Creative BioMart, a biotechnology company focused on protein-related research solutions, has recently upgraded its epitope mapping service to better support researchers in therapeutic antibody development, vaccine design, and immunogenicity studies. The updated platform integrates multiple experimental approaches with customizable strategies, enabling more accurate identification of antibody ...
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has announced the expansion and enhancement of its comprehensive Drug Discovery Services to help scientists advance antiviral therapeutic development, including target selection and validation, hit selection and optimization, and preclinical development. These new services will support ...
Creative Biostructure, a leading provider of structural biology services and products, is pleased to announce the expansion of its exosome product line to include a broader range of exosomes isolated from various stem cell lines. This strategic enhancement aims to support and accelerate research in regenerative medicine, drug delivery, and related fields by providing high-quality, stem ...
Changsha, China – Hunan Huateng Pharmaceutical Co., Ltd. (Huateng Pharma), a global leader in the development and production of high-quality PEG derivatives, is pleased to announce that its mPEG-pALD (20K) has successfully completed its Drug Master File (DMF) filing with the U.S. Food and Drug Administration (FDA), under DMF No. 040600. This achievement highlights Huateng Pharma’s ...